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The EGF-like domain of smallpox growth factor (SPGF) targets human ErbB-1, inducing tyrosine 
phosphorylation of certain host cellular substrates via activation of the receptor’s kinase domain and thereby 
facilitating viral replication. Given these findings, low molecular weight organic inhibitors of ErbB-1 kinases 
might function as antiviral agents against smallpox. Here we show that CI-1033 and related 4-anilinoquin-
azolines inhibit SPGF-induced human cellular DNA synthesis, protein tyrosine kinase activation, and c-Cbl 
association with ErbB-1 and resultant internalization. Infection of monkey kidney BSC-40 and VERO-E6 cells 
in vitro by variola strain Solaimen is blocked by CI-1033, primarily at the level of secondary viral spreading. 
In an in vivo lethal vaccinia virus pneumonia model, CI-1033 alone promotes survival of animals, augments 
systemic T cell immunity and, in conjunction with a single dose of anti-L1R intracellular mature virus particle-
specific mAb, fosters virtually complete viral clearance of the lungs of infected mice by the eighth day after 
infection. Collectively, these findings show that chemical inhibitors of host-signaling pathways exploited by 
viral pathogens may represent potent antiviral therapies.
Introduction
Chemotherapeutic approaches to the control of viral infections 
have been less successful than those against bacterial infections 
because of the need of viruses to replicate in host cells and the 
attendant difficulty in selectively targeting the virus without dam-
aging the host. To date, virtually all strategies for the development 
of antiviral drugs have focused on unique properties of the viral 
replicative cycle or of viral proteins that can be selectively targeted 
(1–3). These drugs include nucleoside analogues and inhibitors of 
viral polymerase, protease, and fusion proteins. Most of the antivi-
ral drugs currently in use are directed against persistently infecting 
viruses, such as HIV, where therapy is expected to continue for a 
long duration. Acute viral infections, however, may need only a 
short period of drug treatment to shift the balance between over-
whelming and lethal virus load on the one hand and an effective 
and protective immune response on the other. Because viruses are 
dependent on host-cell functions for their replication, we ques-
tioned whether a transient and well-tolerated interference of the 
normal functions of the cell types in which the virus replicates 
may retard viral replication and/or spread and spare the host from 
morbidity or mortality.
Smallpox was due to infection with variola major or variola 
minor of the orthopox genus, which belong to the poxvirus family 
of large double-stranded DNA viruses replicating in the cytoplasm 
of infected cells (4). Cessation of vaccination efforts more than 2 
decades ago has resulted in susceptibility of a large segment of the 
population to this pathogen (5). This vulnerability requires addi-
tional methods to rapidly contain any future outbreak of infec-
tions from this group of viruses.
EGF-like growth factors are carried by poxviruses to facilitate viral 
pathogenesis. Prominent skin manifestations elicited by a number 
of these viruses are probably linked to this gene product (4). Prior 
gene deletion studies showed that vaccinia growth factor (VGF) 
of the variola-related orthopox vaccinia virus (VV) contributes to 
virulence following intracranial inoculation of mice and intrader-
mal inoculation of rabbits (6). Likewise, inactivation of myxoma 
growth factor in the distantly related leporipoxvirus diminishes 
viral-induced proliferation of epithelial cell layers in conjunctival 
and respiratory tracts (7). Since smallpox growth factor (SPGF) uses 
ErbB-1 to stimulate host cells (8), thereby aiding viral replication, we 
reasoned that if the viral factor’s stimulatory activity was blocked, 
then viral growth might be curtailed.
The ErbB 1–4 molecules are members of the receptor tyrosine 
kinase superfamily and share common structural features, includ-
ing an extracellular ligand–binding domain, a transmembrane seg-
ment, and an intracellular protein tyrosine kinase (PTK) domain 
(ref. 9 and references therein). These receptors mediate physiologic 
growth factor signaling by EGF, TGF-α, epiregulin, amphiregulin, 
and neuregulin, among other growth factors. Although related, 
there are evident differences in the substrate specificity, signal-
ing properties, and physiology of these receptors. ErbB-2 has no 
known extracellular ligand, and tyrosine kinase activity is absent 
in ErbB-3. In addition, heterodimerization and homodimeriza-
tion of ErbB members contribute to signaling complexity, form-
ing a multilayered network of functional interaction in higher 
eukaryotes, unlike the single, primordial ErbB homologue found 
in Caenorhabditis elegans and Drosophila (9). Since more than 60% 
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of human tumors contain ErbB abnormalities, including receptor 
overexpression via gene amplification and/or rearrangement and 
ErbB receptor–specific ligand aberrations, which contribute to 
the malignant phenotype (9), approaches have been developed to 
block ErbB signal transduction. Clinical inhibitors of ErbB recep-
tor tyrosine kinase pathways are being extensively investigated as 
anticancer agents in many human malignancies (10, 11).
The present study was conducted to determine whether such 
inhibitors might block orthopox infection and the effects of the 
EGF-like pathogenic factors in vitro and in vivo. We show here 
that chemical interference with the signal transduction mediated 
by ErbB-1 can lead to the control of variola virus in vitro and of 
VV in vivo. Thus, targeting of a host cell signal transduction func-
tion needed for viral replication can be used as a new approach to 
antiviral chemotherapy.
Results
Identification of the 4-anilinoquinazoline CI-1033 as an inhibitor for SPGF 
action. Given the high affinity of SPGF for ErbB-1 (Kd = 0.14 nM) 
(8), we evaluated several tyrosine kinase inhibitors belonging to 
the 4-anilinoquinazolines that have strong selective specificity 
for ErbB (Figure 1A). The structure of the ErbB-1 receptor kinase 
domain alone and in complex with one such inhibitor indicates 
how these 4-anilinoquinazolines bind to the ATP-binding pocket 
of the kinase domain (12). Figure 1A shows that PD153035 and 
PD168393 have an identical 4-(3′-bromo-aniline) ring but differ 
in the R3 and R4 groups attached to the quinazoline ring. In par-
ticular, PD168393 has an acrylamide at position 6 which can alkyl-
ate ErbB-1 Cys773 so that the inhibitor irreversibly binds to ErbB-1 
at a 1:1 M ratio. The tyrosine kinase–active ErbB-2 and ErbB-4 
molecules have comparable cysteine residues at Cys784 and Cys778, 
respectively, which can be targeted for modification. In contrast, 
PD153035 binds in a reversible manner, primarily via hydrophobic 
forces. CI-1033, like PD168393, has the R3 acrylamide adduct at 
the 6 position as well as the solubilizing morpholine side chain at 
the 7 position (R4). CI-1033 demonstrates IC50 values of 0.8, 19, 
and 7 nM for ErbB-1, ErbB-2, and ErbB-4, respectively (13). Figure 
1B represents our optimized molecular model for the binding of 
CI-1033 into the ATP pocket cleft found between the 2 major lobes 
of the ErbB-1 kinase domain prior to and after formation of the 
Cys773 adduct (14) and is based on the crystal structure of the com-
plex between the ErbB-1 kinase domain and OSI-774, a chemically 
related 4-anilinoquinazoline (12).
To examine the effects of the 4-anilinoquinazolines on SPGF-
triggered activation of human epithelial cells, a series of in vitro 
experiments was performed. As shown in Figure 2A, after overnight 
stimulation of human fibroblasts with various concentrations of 
recombinant SPGF produced and purified as detailed elsewhere 
(8), the number of cells entering S phase approached 8%. Pretreat-
ment of cells for 1 hour at 37°C with 50 nM concentrations of 
the indicated inhibitors blocks this increase in DNA synthesis. 
Figure 2B shows that these same compounds inhibit tyrosine 
phosphorylation of ErbB-1 (150 kDa band) as well as additional 
substrates (120 kDa, 80 kDa, 60 kDa, and 55 kDa) triggered by 
SPGF in HeLa cells. The Src family PTK-specific inhibitor PP2 does 
not block the phosphorylation of these ErbB-1 substrates even 
when used at 10 μM. In contrast, addition of PD168393 or CI-1033 
at 50 nM largely prevents SPGF-triggered phosphorylation while 
the effect with PD153035 is only modest at best. These results sug-
gest that reversible inhibitors of kinase activity may be less effi-
cient at blocking substrate tyrosine phosphorylation compared to 
irreversible inhibitors at the 50 nM concentration tested. Similar 
inhibition of tyrosine kinase phosphorylation was observed with 
the vaccinia VGF ortholog (data not shown).
The Figure 2C inset shows the distribution of ErbB-1 receptors 
in human HeLa epithelial cells prior to or 15 minutes after SPGF 
addition at 37°C as detected by immunofluorescence microscopy. 
In the absence of growth factor addition, the distribution of ErbB-1 
is primarily confined to the plasma membrane. In contrast, after 
SPGF exposure, ErbB-1 molecules are rapidly internalized, appear-
ing as punctate intracellular fluorescent aggregates. To assess 
whether tyrosine kinase inhibitors influence the ability of SPGF 
to downmodulate ErbB-1, A431 cells were pretreated with inhibi-
tors, incubated with biotinylated SPGF, and shifted to 37°C for 5 
minutes; this was followed by fixation. Cell surface-bound ErbB-1 
ligand was then visualized with streptavidin-PE and quantitative 
fluorescence determined by FACS analysis. Without inhibitors, 
mean fluorescence intensity (MFI) was approximately 110 (Figure 
2C). In contrast, the irreversible ErbB inhibitors augmented MFI 
Figure 1
Structure of ErbB tyrosine kinase inhibitors. (A) Chemical structures of 
ErbB tyrosine kinase inhibitors. (B) Molecular model of CI-1033 inter-
action with the ErbB-1 kinase domain. The upper panel shows the 
model of the noncovalently bound CI-1033 in the ATP-binding site of 
the tyrosine kinase ErbB-1 (protein data bank: 1M17) crystal structure. 
The Tarceva compound was removed, and CI-1033 was manually 
modeled into the site. The backbone of the kinase is shown as a rib-
bon diagram along with the atoms of Cys773. The lower panel shows 
the model of the covalently bound CI-1033 in the ATP-binding site. The 
atoms are shown as stick models with carbon atoms colored white, 
oxygen atoms red, nitrogen atoms dark blue, sulfur atoms yellow, and 
hydrogen atoms light blue.
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approximately 3-fold (to 300–350) whereas the reversible ErbB-1 
inhibitor PD153035 increases MFI to 240. The Src family kinase 
inhibitor PP2 only modestly affects ErbB-1 surface copy number.
The ErbB receptors are eliminated by 2 pathways: (a) ligand-
dependent endocytosis and degradation involving a c-Cbl ubiquitin 
ligase mechanism (15) and (b) stress-induced shuffling of chaper-
ones associated with these receptors and involving proteasomal 
proteinases (16). Recent studies show that ErbB-2 kinase inhibi-
tion by CI-1033 promotes downregulation of ErbB-2 via the sec-
ond process (17). However, given that CI-1033 enhances ErbB-1 
surface expression, the findings suggest that the effects of CI-1033 
on ligand-specific downregulation of ErbB-1 expression are not 
analogous to those on constitutive ErbB-2 expression. To exam-
ine whether 4-anilinoquinazolines might influence c-Cbl interac-
tion with ErbB receptors, inhibitor-pretreated or untreated SPGF-
stimulated HeLa cells were immunoprecipitated with anti–ErbB-1 
antibodies. Subsequently, Western blotting was performed with 
either anti–ErbB-1 antiserum to quantitate expression of ErbB 
molecules or with anti–c-Cbl to assess the effects of the compounds 
on ErbB-1 association. As shown in Figure 2D, compared 
to unstimulated cells (–), the SPGF-triggered HeLa cells (+) 
had less total ErbB-1 due to rapid intracellular degradation. 
Consistent with what FACS analysis showed (Figure 2C), 
PP2 had little influence on this process. On the other hand, 
PD153035, PD168393, or CI-1033 pretreatment augment-
ed the total ErbB-1 protein immunoprecipitated, despite 
SPGF addition; note the several-fold increase in ErbB-1 (i.e., 
EGFR) over the SPGF-unstimulated control cells. The latter 
result implies blockade of constitutive internalization/deg-
radation of ErbB-1 as well. More importantly, SPGF-induc-
ible c-Cbl association with ErbB is blocked by the 4-anilino-
quinazolines but not by PP2. Loss of c-Cbl/ErbB-1 complex 
formation is not secondary to reduction in total cellular 
c-Cbl levels as shown by parallel c-Cbl immunoprecipitation 
and Western blotting. Instead, these ErbB kinase inhibitors 
prevent the inducible association of c-Cbl with ErbB-1 sub-
sequent to SPGF binding.
Effect of CI-1033 on orthopox virus replication and spread. To 
examine the effect of CI-1033 on variola virus growth, a 
confluent monolayer of BSC-40 or VERO-E6 monkey 
kidney epithelial cells was infected with approximately 
50 plaque-forming units of variola strain Solaimen in the 
presence or absence of various concentrations of the ErbB 
inhibitor and cultured in vitro for 4 days. As shown in Fig-
ure 3A of the immmunohistochemical-stained BSC-40 
monolayer, increasing concentrations of CI-1033 dramati-
cally reduced the size of the individual plaques and comet 
formation but had minimal effect on plaque number. This 
effect is titratable (Figure 3, A–C), and at the highest con-
centration of 10 μM, extremely small plaques are faintly 
visible. Although the total number of plaques at the high-
est concentrations of compound appears to decrease, the 
difference is not statistically significant (P > 0.05) when 
compared with 7 randomly selected control wells (Figure 
3, A and B). Figure 3C illustrates a statistically significant 
decrease in the number of comets (P < 0.05) at CI-1033 
concentrations of 500 nM or greater. Comets are repre-
sentative of extracellular-enveloped virus (EEV) formation 
and dissemination (15). Similar qualitative observations 
are made when vaccinia strain IHDJ plaque morphology is 
observed (see Supplemental Figure 1; supplemental material avail-
able online with this article; doi:10.1172/JCI200523220DS1.). A 
role for VGF is implied by the somewhat smaller plaque size and 
markedly reduced comet formation observed with the VV growth 
factor deletion mutant (vSC20, i.e. VGF–) relative to its Western 
Reserve (WR) parent, as demonstrated on the BSC-40 (see Supple-
mental Figure 1, inset) and VERO-E6 cells (data not shown). At 
concentrations of up to 1 μM CI-1033, no effect is observed on 
the minimal comets made by vSC20, but clear reduction in comet 
formation is evident for WR (see Supplemental Figure 1, inset).
Consistent with these findings, a single-step growth curve of 
variola strain Solaimen in VERO-E6 cells demonstrates a delay in 
EEV formation (see Figure 3D, left panel) and a net reduction in 
EEV numbers by greater than 2 logs at 10 μM CI-1033. A decrease 
of less than 1 log in the overall amount of cell-associated virus 
(CAV) comprising intracellular mature virus (IMV) and cell-asso-
ciated enveloped viral particles was observed (Figure 3D, right 
panel). Evaluating single-step growth-curve kinetics in BSC-40 
cells demonstrates a less dramatic 1–2 log decrease in EEV with 
Figure 2
Functional effects of SPGF are blocked by ErbB inhibitors. (A) Inhibition of 
human foreskin fibroblast proliferation by ErbB inhibitors. Human fibroblasts 
were treated and processed as described in Methods. Percentage of cells 
entering S phase is plotted. Gray area represents the baseline S phase after 
serum starvation. (B) Inhibitors block cellular protein tyrosine phosphorylation 
triggered by SPGF. HeLa cells were pretreated with 50 nM inhibitors (PP2, 10 
μM) at 37°C for 30 minutes and then stimulated with 50 ng/ml SPGF at 37°C 
for 15 minutes. Minus (–) indicates no inhibitors or SPGF, and plus (+) indi-
cates SPGF addition only. Total cell lysates were analyzed by Western blotting 
(WB) with 4G10 anti-phosphotyrosine (P-Y) mAb. Arrows indicate positions of 
phosphorylated substrates affected by ErbB-1 inhibition. Numbers on left side 
of the panel indicate the molecular marker in kDa. (C) ErbB-1 internalization 
prevented by inhibitors. A431 cells were pretreated and processed as described 
in Methods. MFI is recorded by FACS. Results are representative of 3 indepen-
dent experiments. The inset shows the ErbB-1 cellular distribution pattern in 
HeLa cells in the absence (–) or presence of SPGF. (D) Inhibitors block asso-
ciation of ErbB-1 and c-Cbl and subsequent ErbB-1 degradation. HeLa cells 
were pretreated with inhibitors and stimulated (37°C, 5 minutes) with SPGF 
as above. Total cell lysates were immunoprecipitated (IP) with anti-EGFR or 
anti–c-Cbl and subjected to Western blot with either antibody.
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10 μM CI-1033 (data not shown). Kinetic evaluation of levels of 
viral DNA (Figure 3E) in VERO-E6 cells under conditions of high 
multiplicity infection shows no inhibition of viral DNA accu-
mulation. No evidence of cytotoxicity due to 500 nM or 10 μM 
CI-1033 was observed in uninfected BSC-40 cells or VERO-E6 
cells by either a lactate dehydrogenase assay (see Supplemental 
Table 1) or trypan blue uptake (data not shown). These aggregate 
results suggest that CI-1033 does not block primary entry and ini-
tiation of viral replication but rather some specific step(s) in viral 
morphogenesis. Functionally, the release of EEV appears sensitive 
to inhibition. Orthopox viruses use both microtubule and actin 
filaments for egress (16, 17) with cell-associated enveloped virus–
inducing (CEV-inducing) actin tails to eject themselves from the 
cell. As ErbB-1 activation reorganizes the actin microfilament 
system (18), it appears likely that both CEV and EEV release are 
blocked, retarding secondary virus cell-to-cell spread and hence 
limiting the size of individual plaques.
Note that the specificity of CI-1033 for ErbB family members 
is approximately 100,000-fold greater than for unrelated kinases 
such as PDGF receptor, FGF receptor, insulin receptor, and cyclins 
D1, A and B (13, 14). This makes a nonspecific effect extremely 
improbable for doses of CI-1033 that are less than or equal to 1 μM. 
On the other hand, inhibition of the VGF– WR variant at the 2 
highest drug concentrations (see Supplemental Figure 1, inset) 
implies either that additional endogenous growth-factor signaling 
via EGFR is blocked or that inhibition of other viral-egress–rel-
evant tyrosine kinase activation cascades has occurred. By exten-
sion, this mechanism(s) applies to vaccinia strains IHDJ and WR 
and variola viruses. The more profound related effect on long-range 
dissemination of virus via EEV suggests additional mechanisms of 
interference. Because EGFR endocytosis is also linked to the actin 
cytoskeleton (18), ErbB-1 kinase inhibition may serve to 
maintain surface EGFR expression via this mechanism as 
well (Figure 2C). More importantly, the ability of CI-1033 
to block EGFR activation by cellular ErbB ligands or trans-
stimulation of ErbB-1 via other receptors as well as its down-
stream effects on cytoskeletal elements used for poxvirus 
egress likely accounts for the profound effect on plaque 
morphogenesis not observed with anti-SPGF mAbs (8).
Control of VV infection in vivo by CI-1033. Disruption of the 
VGF gene in vaccinia WR was shown to reduce pathogenic-
ity of VV in vivo by inhibiting viral growth and shifting the 
LD50 2,000-fold (6). Since CI-1033 blocks SPGF-stimulat-
ed, ErbB-1–driven cell growth, receptor-mediated tyrosine 
phosphorylation, internalization, and degradation, and in view 
of its antiviral activity in vitro noted above, we reasoned that the 
ErbB-1 kinase inhibitor may attenuate orthopox growth factor 
activity in vivo. To test this possibility, the effect of CI-1033 on the 
clinical course of B6 mice given an intranasal (i.n.) vaccinia WR 
challenge (19) was examined. This dose was close to the LD50, so 
there was some variation in lethality between different experiments 
with mice of slightly different ages. Figure 4A shows an experiment 
with 7-week-old mice inoculated with 104 PFU in which all (5 of 
5) untreated mice died from a fulminant acute pneumonia by day 
7 after infection. In contrast, i.p. administration of CI-1033 at 50 
mg/kg beginning 6 hours prior to infection and continuing daily 
for 8 days prevented death for the duration of the experiment. In a 
second experiment with 9-week-old mice inoculated with 104 PFU 
in which drug treatment was stopped at day 5, 3 of 4 control mice 
were dead by day 9, but 5 of 5 mice treated with drugs remained alive 
at day 10, although 3 of 5 succumbed by day 14 (data not shown). 
In a third experiment with 5-week-old mice receiving 2 × 104 PFU 
in which drug treatment stopped after 7 days, 4 of 4 untreated 
and 0 of 5 drug-treated mice died by day 9, 2 of 5 treated mice died 
at day 10, and 3 of 5 survived for the duration of the experiment 
(data not shown). These experiments indicate that treatment with 
the drug alone could consistently either delay or inhibit death in 
response to this lethal dose of virus. Treatment with a single 200 
μg i.p. dose of anti-L1R VV mAb (7D11) known to neutralize the 
IMV particles could also protect mice from the lethal effects of i.n. 
inoculation, as could combined anti-L1R and CI-1033 treatment 
(Figure 4A). Clinical monitoring of animals after infection showed, 
however, that combined treatment with anti-L1R and CI-1033 
reduced symptomatology significantly better than either treatment 
alone (Figure 4B). The efficacy of combined treatment was further 
Figure 3
Prevention of secondary variola virus spreading in vitro by 
ErbB kinase inhibition. (A) Immunohistochemical staining of 
variola strain Solaimen plaques on monolayers of BSC-40 cells 
after 4 days in the presence (+) or absence (–) of indicated M 
concentrations of CI-1033. (B) Titration effect of CI-1033 on 
variola plaque formation. (C) Titration effect of CI-1033 on vari-
ola comet formation. Asterisks indicate statistically significant 
differences (P < 0.05) from 7 randomly selected control wells. 
(D) Time course of variola virus production (single-step growth 
curve) on VERO-E6 cells in the absence (untreated) or pres-
ence of indicated concentration of CI-1033 with left and right 
panels showing EEV and CAV titers, respectively. (E) Viral 
DNA genome copies from variola single-step growth curve in 
VERO-E6 cell in the absence (untreated) or presence of 500 
nM or 10 μM CI-1033.
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illustrated in an experiment in which 8-week-old mice were given a 
higher dose of 5 × 104 PFU VV. Mice in all groups died except those 
with combined therapy, of which 80% (4 of 5) survived.
A cohort of animals was sacrificed at 8 days after infection and 
their lungs examined. Differences among gross lung weight in each 
treatment group are shown in Figure 4C. Untreated animals had 
edematous lungs with multiple hemorrhages, weighing nearly 2 
times as much as normal, uninfected B6 lungs. This pathology was 
somewhat attenuated by anti-L1R or CI-1033 treatment alone but 
dramatically ameliorated by the combination of CI-1033 and anti-
L1R (see Supplemental Figure 2). In 5 experiments, treatment with 
CI-1033 alone (1 mg/d) only modestly reduced viral lung titers 
compared to those of untreated infected controls (day 6a, reduced 
0.42 log10 PFU; day 6b, reduced 0.14 log10 PFU; day 7, reduced 0.20 
log10 PFU; day 8a, reduced 0.08 log10 PFU; day 8b, reduced 0.50 
log10 PFU, where a and b refer to independent experiments). This 
contrasts with the more efficacious anti-L1R in the same experi-
ments (day 6a, reduced 1.1 log10 PFU; day 6b, reduced 0.54 log10 
PFU; day 7, reduced 1.2 log10 PFU; day 8a, reduced 2.2 log10 PFU; 
day 8b, reduced 5.0 log10 PFU). Combined treatment, however, 
tended to reduce viral titers by greater amounts as shown in these 
experiments (day 6a, reduced 1.4 log10 PFU; day 6b, reduced 1.3 
log10 PFU; day 7, reduced 2.9 log10 PFU; day 8a, reduced 5.1 log10 
PFU; day 8b, reduced 5.4 log10 PFU). In these experiments, in which 
control mice survived, and in another (Figure 4D), in which con-
trol mice died, we noted that combined treatment was particularly 
effective at reducing viral titers by day 7–8 after infection. We have 
previously observed that mAbs to SPGF that cross-react with VGF 
can also synergize with anti-L1R to reduce VV lung titers by day 
8 (8). Figure 4D shows the enhancing effects of anti-SPGF and of 
CI-1033 in combination with anti-L1R at 8 days after infection 
in an experiment in which untreated control animals died and 
could not be titrated for infectivity (although 7–8 log10 PFU are 
observed in other experiments). Thus, the CI-1033 drug can appar-
ently replace anti-SPGF mAbs in therapy against VV. The further 
2-log viral titer reduction with anti-L1R plus CI-1033 compared 
with anti-L1R plus anti-SPGF therapy noted in Figure 4D may be a 
consequence of the irreversible binding of the drug (14) compared 
with reversible mAb binding, affording a more complete block-
ade with CI-1033 of the ErbB-1 pathway along with inhibition of 
endogenous host ErbB ligands. Another explanation may be that 
CI-1033 blocks dissemination of EEV. In vivo pharmacokinetic 
studies in mice at the dose range employed herein show peak plas-
ma levels of CI-1033 of 2.2 μM, a concentration inhibiting comet 
formation in vitro (Figure 3 and data not shown).
We consistently noted that mice treated with CI-1033 alone or 
in combination with anti-L1R mAb had less morbidity and looked 
much healthier than non–drug-treated controls, even under condi-
tions in which there were only minor differences in lung viral titers. 
This may have been due in part to the more effective control of 
the progression of infection in other organs. In the liver, for exam-
ple, there were nearly 100-fold lower titers of virus in drug-treated 
groups by day 5 after infection (day 5, control, 4.6 log10 PFU, vs. 
drug-treated, 2.8 log10 PFU, P = .02; day 7, control, 4.7 log10 PFU, vs. 
drug-treated, 3.0 log10 PFU, P = .003). Correspondingly, the number 
and size of inflammatory foci in the livers were much reduced in 
the drug-treated mice.
Augmentation of antiviral host response. In the combination anti-
L1R plus anti-SPGF immunotherapy model (8), augmented T cell 
responses to VV were detected by day 6 after infection. To deter-
mine whether CI-1033 alone or in combination with anti-L1R may 
augment T cell responses, we examined T cell–regulated cytokine 
production in lungs by RNase protection analysis at days 4, 6, and 
8 after infection. As shown in Supplemental Figure 3A, compared 
to what occurred in untreated mice, the use of CI-1033 alone 
augmented IL-1β, IL-1 receptor antagonist (IL-1Ra), and IFN-γ, 
peaking at day 6, without influencing IL-6, IL-10, IL-12, or migra-
tion inhibitory factor (MIF). For example, the IFN-γ signal was 
4.1-fold greater on day 6 with CI-1033–treated mice relative to the 
control infected animals. Consistent with the lung cytokine level, 
systemic antigen-specific T cell responses to VV-infected MC57G 
fibroblasts (H-2b) were augmented substantially by CI-1033 rela-
tive to control untreated mice as judged by splenic CD8+CD44+ 
intracellular IFN-γ production (see Supplemental Figure 3B). The 
percentage of VV-MC57G–activated, IFN-γ–producing CD8+ T 
cells was 10-fold higher than in untreated VV-infected mice on day 
8 after infection; this corresponds to a 21-fold increase in absolute 
number (1.85 × 105 control cells vs. 8.5 × 103 drug-treated cells). In 
the same experiment, 23- and 48-fold increases were observed for 
anti-L1R– and anti-L1R plus CI-1033–treated mice, respectively. 
That anti-L1R treatment leads to more IFN-γ cytokine RNA in the 
lung than the anti-L1R plus CI-1033 dual therapy (see Supplemen-
tal Figure 3) may be indicative of persistent viral load, particularly 
at day 8 after infection, with the former treatment (Figure 4D). In 
sum, chemotherapy alone and combination immunoprophylaxis/
chemotherapy are efficient at reducing viral titer and stimulating 
T cell immunity. The latter may be a consequence of preventing 
Figure 4
Rescue of mice from lethal vaccinia pneumonia by an ErbB inhibitor. 
(A) Mouse survival curves after i.n. vaccinia inoculation following pre-
treatment with CI-1033 (1 mg/mouse/day) and/or anti-L1R (200 μg i.p. 
6 hours before inoculation). Note that all control mice died by day 7. 
Each treatment group includes a cohort of 5 animals. (B) Clinical score 
of mice during treatment. The score (0–4) is explained in Methods and 
is the mean value of the 5 mice per group. (C) Average weight of the 
entire lung 6 days after lethal vaccinia infection with or without indi-
cated treatment (n = 3 per group) versus normal, uninfected lung. (D) 
Virus titers in lungs at day 8 after infection. Results are representative 
of 5 experiments.
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the elaboration of antiinflammatory viral products as well as later 
rounds of DNA virus replication in epithelial cells dependent on 
the viral growth factor (20, 21). Given these data, we perceive a 
linkage between viral growth, viral spreading, and host immunity 
as modulated through SPGF/VGF and ErbB-1 interaction.
Postexposure therapy. Current interest in orthopox virus thera-
peutics stems from concerns that variola virus may be used as a 
bioterrorism agent. Hence, postexposure therapy protocols may 
be needed as an alternative to postexposure vaccination. We there-
fore tested the efficacy of CI-1033 as a postexposure therapeutic 
agent, with and without mAb-dependent immunotherapy. The 
i.n. VV infection of mice rapidly progresses, unlike the slow incu-
bation time for development of symptoms in humans after expo-
sure to variola (4, 5). Successful therapy in this rapidly progressing 
VV murine model would thus provide promise for possible drug 
intervention in human infections. Mice (7–10 weeks of age) were 
therefore inoculated i.n. with 2 × 104 PFU VV for 2 days to allow for 
substantial replication of VV, prior to subsequent therapeutic inter-
vention. An initial survival experiment showed that drug treatment 
alone did not prevent lethality, which was prevented by mAb L1R, 
with or without CI-1033 (data not shown). Figure 5 summarizes 
results in 3 other experiments after 4 (day 6), 5 (day 7), and 6 (day 
8) days of therapy. Drug treatment alone provided no protection 
by itself by day 6, though it appeared to augment the protective 
effect of anti-L1R, in regard to lung weight and lung titers. Those 
parameters did not reach statistical significance, but by this early 
time point, a statistically significant increase in anti-CD3–induced 
IFN-γ–producing CD8+ T cells per spleen was seen with combined 
therapy. By day 7 the same trends were observed, with combined 
therapy resulting in lower lung weights and viral titers and now 
dramatically (6-fold) increased T cell responses. Clinical scores 
(scoring system as described in Methods and ref. 8) were substan-
tially improved in the combined therapy group at day 7 (untreated, 
4.0 ± 0; L1R, 3.4 ± 0.6; L1R plus CI-1033, 2.4 ± 0.5). By day 8, 4 out 
of 5 of the untreated controls had died, as expected. In compari-
son to what occurred in L1R-treated mice, there were statistically 
significant reductions in lung viral titers (P = 0.02) in the com-
bined therapy group, which also had reduced lung size, substantial 
splenomegaly, and more than 3 times the number of VV-specific T 
cells in the spleen. The heightened T cell response at day 8 allowed 
for the examination of VV-specific CD8+ T cells, as determined by 
their production of IFN-γ after incubation with VV-infected DC2.4 
dendritic cells. VV-specific T cell responses increased greater than 
3-fold in mice receiving combined therapy (11.4 ± 3.3 × 105) com-
pared to those receiving only mAb L1R therapy (3.2 ± 4.2 × 105; 
P = 0.002). These experiments demonstrate the postexposure effi-
cacy of CI-1033 when used in combination with immunotherapy.
Discussion
Recently we characterized SPGF, a protein containing an EGF-like 
domain that is conserved among orthopox viral genomes, and inves-
tigated its possible mechanistic link to skin manifestations associ-
ated with smallpox (8). We showed that after recombinant expres-
sion, refolding, and purification, the EGF domain of SPGF bound 
exclusively to the broadly expressed cellular receptor, ErbB-1 (EGFR), 
with sub-nM affinity, stimulating the growth of primary human 
keratinocytes and fibroblasts. High-affinity mAbs specific for SPGF 
revealed in vivo immunoprotection in a murine vaccinia pneumonia 
model through a mechanism distinct from viral neutralization. These 
findings suggested that blockade of pathogenic factor actions, in gen-
eral, may be advantageous to the infected host. Given that ErbB-1 is 
the host target for SPGF, the possibility that chemical inhibition of 
ErbB-1 signaling might offer host protection was investigated.
The use of host cellular signaling pathway blockade as a target for 
antiviral chemotherapy is distinct from other approaches typically 
directed against pathogens themselves. One advantage of the host-
targeted strategy is that drug resistance cannot readily develop. Fur-
thermore, unlike anti-SPGF mAbs (8), where cross-reactivity with 
other closely related pathogenic factors (i.e., VGF vs. SPGF) is not 
guaranteed, the ErbB inhibitors are potentially able to block immu-
nologically distinct ligands to various ErbB PTK family members. 
This broader target activity is relevant since, for example, VGF and 
myxoma growth factor bind distinct ErbB receptors (22). Whether 
CI-1033 by itself would be a sufficient therapy against variola virus 
infection remains to be determined but appears possible given that 
the dose of orthopox particle inhalation from natural or bioterrorist 
spread is likely to be less than that employed in the current study, 
and the time course for the progression of smallpox in humans is 
much longer than in the VV-infected mouse model. In addition, the 
drug dosing and scheduling has yet to be optimized. How efficiently 
postexposure therapy might thwart clinical infection now requires 
careful scrutiny. That CI-1033 augments T cell responses while 
reducing infectious symptomatology also suggests its consideration 
as an immune stimulant postvaccinia vaccination with possible util-
ity in the treatment of complications of immunization. Other ErbB 
inhibitors (23, 24) may also be useful in this regard.
Figure 5
Postexposure therapy of VV infection in the C57BL/6 pneumonia model. Mice were inoculated i.n. with 2 × 104 PFU of VV, and 2 days later were 
treated with a single dose of mAb L1R or control mAb and/or with CI-1033, the latter given daily until termination of the experiment. Mice were 
sacrificed on different days after infection and examined for lung weight (A), VV PFU/lung (B), and the number of anti-CD3–induced IFN-γ–produc-
ing CD8+ T cells per spleen (C). For days 6, 7, and 8, group sizes of 3–4, 5, or 6 animals, respectively, were employed. At day 8, 2 of 6 anti–L1R-
treated mice had undetectable virus, whereas 5 of 6 anti-L1R plus CI-1033–treated mice had undetectable virus. For calculation of mean titers, the 
lowest detectable titer possible (1 log) was used for mice without detectable virus, such that the means are actually lower values. *P < 0.05.
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Aside from poxviruses and their ErbB-directed growth factors, 
hepatitis B virus and Epstein-Barr virus elaborate factors that 
dysregulate ErbB-1 transcription (25, 26). RNA tumor viruses also 
exploit ErbB-1 signaling (27). In addition, functional EGF receptors 
have been reported to be necessary for efficient reovirus (28) and 
human cytomegalovirus infection of host cells (29). These findings 
collectively suggest that multiple viral infections may be coupled to 
the ErbB-mediated signaling network. Epithelial cells, which con-
stitutively or inducibly express ErbB receptors, are common sites 
of viral replication (30). Perhaps ErbB inhibitors will have wider 
application in infectious diseases beyond those involving orthopox 
viruses. Development of chemical inhibitors of cellular signaling 
pathways exploited by viral pathogenic factors may offer a new 
approach toward infectious disease control in general.
Methods
Chemical inhibitors. CI-1033 was provided by Pfizer Inc. PP2, PD153035, and 
PD168393 were purchased from Calbiochem.
Human fibroblast proliferation assay. Human foreskin fibroblasts (SC-J) 
were plated in 6-well plates and starved overnight in 2% FCS-DMEM medi-
um, then pretreated with inhibitors for 1 hour at 37°C; this was followed 
by stimulation with different amounts of SPGF. The cells were harvested 
18 hours later and fixed in 80% ice-cold ethanol at 4°C for 1 hour. After a 
single wash with PBS, cells were stained with 2.5 μg/ml propidium iodide 
and 50 μg/ml RNase A at 37°C for 30 minutes. Cell cycle data were col-
lected by FACS analysis using Cellquest (BD Biosciences) and analyzed by 
Modfit (Verity Software House).
ErbB-1 (EGFR) internalization. HeLa cells were cultured on chamber slides 
and stimulated with ligands (50 ng/ml) at 37°C for 10 minutes. Cells were 
then fixed using 3.7% formaldehyde for 10 minutes and permeabilized with 
0.1% Triton X-100 for 5 minutes at room temperature. Cells were stained 
with 1 μg of anti-EGFR mAbs (Santa Cruz Biotechnology Inc.) in 1% BSA/
PBS at room temperature for 30 minutes; this was followed by staining 
with anti-mouse Ig-FITC conjugates.
A431 epidermal carcinoma cells were pretreated with 50 nM inhibitors at 
4°C for 30 minutes. Biotinylated SPGF (100 ng) was incubated with the cells 
for a further 30 minutes at 4°C. After washing, cells were incubated at 37°C 
for 5 minutes and fixed in formaldehyde for 5 minutes at room temperature. 
Subsequent to streptavidin-PE staining, MFI was obtained by FACS.
Cell lysate preparation, immunoprecipitation, and Western blotting. HeLa cells 
were treated with 50 nM inhibitors at 37°C for 30 minutes; this was fol-
lowed by 50 ng/ml SPGF stimulation. Cell lysates were prepared and 
subjected to immunoprecipitation with anti-EGFR (goat polyclonal; 
Santa Cruz Biotechnology Inc.) and GammaBind Plus beads (Amersham 
Biosciences) or anti–c-Cbl beads (Santa Cruz Biotechnology Inc.) at 4°C 
overnight using previously described methods (8). Beads were washed and 
eluted in 2× concentration SDS-PAGE–loading buffer and analyzed by 
Western blotting with either anti-EGFR or anti–c-Cbl.
VV infection of mice. Male C57BL/6 mice aged 4 to 10 weeks were injected 
i.p. with 200 μg anti-L1R (7D11) mAb in PBS and/or 50 mg/kg/d CI-1033 
in 0.05 N sodium lactate buffer, pH 4. Infected control mice were either 
treated with a control mAb in PBS or sodium lactate buffer without drug. 
Six hours later, mice were infected i.n. with 4 × 104 PFU VV, WR strain. 
Each day the mice were weighed and observed for symptoms of infection 
(0 = normal, 1 = ruffled fur; 2 = 1 plus hunched position; 3 = 2 plus little 
locomotion; 4 = 3 plus lethargy and minimal response). Virus titer was 
determined by plaque assay on VERO cells as previously described (31). 
CI-1033 treatment was of 6–10 days duration. Intracellular cytokine stain-
ing of CD8+ T cells was done as previously described, using either anti-CD3, 
VV-infected MC57G cells, or VV-infected DC2.4 dendritic cells (obtained 
from Ken Rock, University of Massachusetts Medical School) to stimulate 
splenic lymphocytes (8). In some experiments, mice were infected with VV 2 
days prior to treatment with mAb and/or CI-1033. All animal experimenta-
tion was performed according to Association for Assessment and Accredi-
tation of Laboratory Animal Care (AAALAC)-approved protocols for ethi-
cal treatment. The work was approved by the University of Massachusetts 
Medical School Institutional Animal Care and Use Committee.
Titration effect of CI-1033 on variola plaque and comet formation. Confluent 
BSC-40 monolayers were pretreated or mock-treated in the presence or 
absence of CI-1033 in RPMI plus 2% FBS (RPMI-2%) at varying concen-
trations in triplicate for 30 minutes at room temperature. Seven concen-
trations of CI-1033 were evaluated; 3 mock-treated controls per each con-
centration of CI-1033 were used on 7 individual 6-well plates. Monolayers 
were infected with a suspension of variola strain Solaimen in the presence 
or absence of CI-1033, such that approximately 50 PFU per well of virus 
were observed. Plates were incubated at 35°C, 6% CO2 for 1 hour and rocked 
at 15 minutes intervals to ensure an even infection of the monolayer. The 
inoculum was removed, and the monolayer was rinsed 1 time with RPMI-2%. 
The monolayers were overlaid with medium ± CI-1033 at the appropriate 
concentrations and incubated at 35°C, 6% CO2 for 4 days. The plates were 
then γ-irradiated at the kill dose (4.4 × 106 rad) and removed from the Bio-
safety Level 4 laboratory for immunohistochemical staining. Plaques were 
immunohistochemically stained for analysis. Comets were defined as 2 
or more successively smaller plaques in comet-shaped association with a 
large plaque. The number of plaques and comets in the presence of differ-
ent concentrations of CI-1033 was compared to that in control plates using 
a Wilcoxon rank-sum test. Seven randomly selected mock-treated wells, 1 
selected from each of 7 plates, were used for comparison.
Molecular modeling. CI-1033 was docked into the ATP-binding site of the 
kinase crystal structure (12) manually, based on the information that the 
compound bound irreversibly to Cys773 (14). The modeling was performed 
with the Sybyl molecular modeling package using the standard (Maximin) 
minimizer with the Tripos force field; hydrogen atoms were included, and 
minimizations were done without charges on any atoms (Tripos). The quin-
azoline ring of CI-1033 was placed in the same orientation and docking 
mode as observed for Tarceva, another ErbB inhibitor (12). Distance con-
straints from the quinazoline N1 to the Met769 backbone NH kept these 
atoms within hydrogen-bonding distance. Also, distance constraints kept 
the C2 hydrogen of the quinazoline ring and the carbonyl oxygen of Gln760 
to the distance observed in the crystal structure. Torsional constraints were 
employed to keep the core ring fully planar. CI-1033 was manually placed 
in the ATP-binding site and the complex minimized, first with the protein 
aggregated to allow the ligand to fit the pocket after manual docking, then 
with the constraints removed and minimized for 400 interations.
For the covalently bound variant, the initial modeling of the noncova-
lently bound variant was the starting point. The sidechain of the CI-1033 
molecule was oriented close to the Cys773 sulfur and the appropriate 
bond formed. All atoms but the ligand and the Cys773 were formed into 
an aggregate, and the system was minimized. This allowed only the ligand 
and Cys773 atoms to move. After minimization with the aggregate, the 
aggregate was removed, and the full system was allowed to minimize for 
400 iterations, still maintaining the distance and torsional constraints.
RNase protection assay. One lobe of lung from each treated mouse at vari-
ous days after infection was disrupted in RLT buffer (QIAGEN) through an 
18-gauge needle. Lysates were further homogenized by QIAshredder mod-
ules and purified using an RNeasy Mini Kit according to the manufacturer’s 
protocol (QIAGEN). Equal amounts of total RNA (2 μg/mouse) were pooled 
from 3 mice at each time point (days 4, 6, and 8). Six μg were hybridized and 
processed with probes made from the mCK-2b template set according to the 
manufacturer’s protocol (BD Biosciences — Pharmingen).
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Variola single-step growth curve in BSC-40 and VERO-E6 cells. Confluent 
BSC-40 and VERO-E6 monolayers were pretreated or mock-treated in the 
presence or absence of CI-1033 in RPMI-2% FBS at 500 nM and 10 μM con-
centrations for 30 minutes at room temperature. Monolayers were infected 
at a MOI of 10 with a suspension of variola strain Solaimen in the pres-
ence or absence of CI-1033 at the appropriate concentrations. Plates were 
incubated at 35°C, 6% CO2 for 1 hour and rocked at 15-minute intervals to 
ensure even infection of the monolayer. The inoculum was removed, and 
the monolayer was rinsed twice with RPMI-2%. The monolayers were over-
laid with media ± CI-1033 at the appropriate concentrations and incubated 
at 35°C, 6% CO2. EEV and CAV were harvested from independent wells in 
triplicate at various time points after infection.
Titrating harvested samples. EEV was harvested by removing a 100-μl ali-
quot of the infection supernatant and serially diluting in 900 μl RPMI-2% 
plus IMV-neutralizing J2D5 mAbs (1:1000). This concentration of mAbs 
was demonstrated to neutralize 99% of IMV. Dilutions were then plated 
onto confluent VERO-E6 cell monolayers and incubated at 35°C, 6% CO2 
for 1 hour  and rocked at 15-minute intervals to ensure even infections 
of the monolayer. The inoculum was removed and the monolayers were 
overlaid with 2 ml RPMI-2% plus J2D5 mAb. Plates were incubated at 
35°C, 6% CO2 for 4 days and counterstained with Crystal Violet (Sigma-
Aldrich) to quantitative plaques. Viral titer was determined by counting 
plaques. CAV was harvested by removing the remaining infection super-
natant after EEV harvest and adding 1 ml fresh RPMI-2% to each well. 
The CAV samples were then titrated using a standard method for ortho-
pox plaque assay (32). A 1-ml aliquot was placed into a labeled tube and 
stored at –80°C until titration.
Viral DNA load. Viral DNA was isolated from CAV time point samples 
using a slight variation of the Bio-Rad Genomic DNA Isolation Protocol 
(Bio-Rad Laboratories Inc.). Viral DNA load was determined using a real-
time PCR method that targets the orthopox virus DNA polymerase.
Cytotoxicity assay. A confluent BSC-40 or VERO-E6 cell monolayer was 
grown in a 6-well plate and treated with various concentrations of CI-1033 
in 2 ml RPMI-2%. The plate was incubated at 37°C, 6% CO2 for 48 hours. 
Media were removed from the cell monolayers and placed into correspond-
ing labeled tubes, and an additional 2 ml RPMI-2% was added to each well. 
Using a 1-cc syringe barrel, cell monolayers were scraped into suspension 
and then removed to labeled tubes. The cell resuspension samples were 
lysed using the freeze/thaw method, followed by centrifugation of all sam-
ples collected at 250 × g for 5 minutes. Cytotoxicity was measured using the 
CytoTox 96 Non-Radioactive Cytotoxicity Assay Kit and protocol (Promega 
Corp.). Absorbance was read at 490 nM and percent cytotoxicity was deter-
mined and expressed as the amount of experimental lactate dehydrogenase 
(LDH) released into the medium ± CI-1033 divided by the maximum pos-
sible amount of LDH released by lysing of the cells (experimental LDH 
release/maximum LDH release). Alternatively, after 48 hours, an equal vol-
ume of Trypan Blue stain was added to each well. Cells were stained for 10 
minutes at room temperature. Stain was removed from the cell monolayer, 
and cells were observed under a microscope for any evidence of stain absorp-
tion, indicating cellular membrane permeability and death.
Online supplemental material. Supplemental Figure 1 shows VV IHDJ 
comet formation and inhibition by CI-1033 in BSC-40 and VERO-E6 
cells. Supplemental Figure 1 inset shows VV WR and VGF deletion mutant 
(vSC20) comet formation and inhibition by CI-1033 in BSC-40 cells. Sup-
plemental Figure 2 shows hematoxylin and eosin staining of lungs from 
VV-infected mice in untreated and experimental groups. Supplemental 
Figure 3 examines whole-lung cytokine expression profiles and IFN-γ 
production in CD8+ T cells in these groups. Supplemental Table 1 shows 
minimal to no cytotoxicity of CI-1033 in experiments performed in par-
allel with the plaque morphology experiments in Supplemental Figure 1. 
Methods of preparation of rabbit antivariola hyperimmune sera and 
immunohistochemical staining of variola plaques are given.
Acknowledgments
This work was supported by NIH grants AI57300 and AI19807, a 
grant from the Dana Foundation (to E.L. Reinherz), and NIH grant 
AR-35506 (to R.M. Welsh). We thank David Fry, Huifen Chen, and 
James B. Dunbar for molecular modeling efforts and helpful dis-
cussions. We acknowledge scientific input from Miles Brown, Ray 
Dolin, Wayne Klohs, and Barrett Rollins. We also acknowledge 
Aaron Curns for statistical support. We thank Bernard Moss for 
providing WR and vSC20 VV strains. We acknowledge the excel-
lent technical assistance of Keisha Mathurin.
Received for publication August 31, 2004, and accepted in revised 
form November 23, 2004.
Address correspondence to: Ellis L. Reinherz, Dana-Farber Can-
cer Institute, 44 Binney Street, Boston, Massachusetts 02115, 
USA. Phone: (617) 632-3412; Fax: (617) 632-3351; E-mail: 
ellis_reinherz@dfci.harvard.edu.
Hailin Yang, Sung-Kwon Kim, Mikyung Kim, and Pedro A. Reche 
contributed equally to this work.
 1. Balfour, H.H. 1999. Antiviral drugs. N. Engl. J. Med. 
340:1255–1268.
 2. Dolin, R. 2001. Antiviral chemotherapy, excluding 
antiretroviral drugs. In Principles of Internal Medicine. 
15th edition. E. Braunwald et al., editors. McGraw-
Hill. New York, New York, USA. 1092–1100.
 3. Fauci, A.S., and Lane, H.C. 2001. Human immu-
nodeficiency virus (HIV) disease: AIDS and related 
disorders. In Principles of Internal Medicine. 15th 
edition. E. Braunwald et al., editors. McGraw-Hill. 
New York, New York, USA. 1852–1913.
 4. Fenner, F., Wittek, R., and Dumbell, K.R. 1988. The 
orthopoxviruses. Academic Press. San Diego, Califor-
nia, USA. 432 pp.
 5. Henderson, D.A., et al. 1999. Smallpox as a biologi-
cal weapon: Medical and public health manage-
ment. JAMA. 281:2127–2137.
 6. Buller, R.M., Chakrabarti, S., Cooper, J.A., 
Twardzik, D.R., and Moss, B. 1988. Deletion of 
the vaccinia virus growth factor gene reduces virus 
virulence. J. Virol. 62:866–874.
 7. Opgenorth, A., Nation, N., Graham, K., and 
McFadden, G. 1993. Transforming growth factor 
alpha, Shope fibroma growth factor, and vaccinia 
growth factor can replace myxoma growth factor in 
the induction of myxomatosis in rabbits. Virology. 
192:701–709.
 8. Kim, M., et al. 2004. Biochemical and functional 
analysis of smallpox growth factor (SPGF) and 
anti-SPGF monoclonal antibodies. J. Biol. Chem. 
279:25838–25848.
 9. Yarden, Y., and Sliwkowski, M.X. 2001. Untangling 
the erbB signalling network. Nat. Rev. Mol. Cell Biol. 
2:127–137.
 10. Cockerill, G.S., and Lackey, K.E. 2002. Small mol-
ecule inhibitors of the class I receptor tyrosine 
kinase family. Curr. Top. Med. Chem. 2:1001–1010.
 11. Wakeling, A.E. 2002. Epidermal growth factor 
receptor tyrosine kinase inhibitors. Curr. Opin. 
Pharmacol. 2:382–387.
 12. Stamos, J., Sliwkowski, M.X., and Eigenbrot, C. 
2002. Structure of the epidermal growth factor 
receptor kinase domain alone and in complex 
with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 
277:46265–46272.
 13. Allen, L.F., Lenehan, P.F., Eiseman, I.A., Elliott, 
W.L., and Fry, D.W. 2002. Potential benefits of the 
irreversible pan-erbB inhibitor, CI-1033, in the 
treatment of breast cancer. Semin. Oncol. 29:11–21.
 14. Fry, D.W., et al. 1998. Specific, irreversible inactiva-
tion of the epidermal growth factor receptor and 
erbB2, by a new class of tyrosine kinase inhibitor. 
Proc. Natl. Acad. Sci. U. S. A. 95:12022–12027.
 15. Soubeyran, P., Kowanetz, K., Symkiewicz, I., Lang-
don, W.Y., and Dikic, I. 2002. Cb1-CIN85-endophilin 
complex mediates ligand-induced downregulation 
of EGF receptors. Nature. 416:183–187.
 16. Xu, W., et al. 2001. Sensitivity of mature ErbB2 to 
geldanamycin is conferred by its kinase domain 
and is mediated by the chaperone protein Hsp90. 
J. Biol. Chem. 276:3702–3708.
 17. Citri, A., et al. 2002. Drug-induced ubiquitylation and 
degradation of ErbB receptor tyrosine kinases: impli-
cations for cancer therapy. EMBO J. 21:2407–2417.
 18. Lynch, D.K., et al. 2003. A Cortactin-CD2-associ-
ated protein (CD2AP) complex provides a novel 
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 115   Number 2   February 2005 387
link between epidermal growth factor receptor 
endocytosis and the actin cytoskeleton. J. Biol. 
Chem. 278:21805–21813.
 19. Chen, H.D., et al. 2001. Memory CD8+ T 
cells in heterologous antiviral immunity and 
immunopathology in the lung. Nat. Immunol. 
2:1067–1076.
 20. Alcami, A. 2003. Viral mimicry of cytokines, 
chemokines and their receptors. Nat. Rev. Immunol. 
3:36–50.
 21. Seet, B.T., et al. 2003. Poxviruses and immune eva-
sion. Annu. Rev. Immunol. 21:377–423.
 22. Tzahar, E., et al. 1998. Pathogenic poxviruses reveal 
viral strategies to exploit the ErbB signaling net-
work. EMBO J. 17:5948–5963.
 23. Fry, D.W., et al. 1994. Specific inhibitor of the 
epidermal growth factor receptor tyrosine kinase. 
Science. 265:1093–1095.
 24. Levitzki, A., and Gazit, A. 1995. Tyrosine kinase 
inhibition: an approach to drug development. 
Science. 267:1782–1788.
 25. Menzo, S., et al. 1993. Transactivation of epidermal 
growth factor receptor gene by the hepatitis B virus 
X-gene product. Virology. 196:878–882.
 26. Miller, W.E., Earp, H.S., and Raab-Traub, N. 1995. 
The Epstein-Barr virus latent membrane protein 1 
induces expression of the epidermal growth factor 
receptor. J. Virol. 69:4390–4398.
 27. Adelsman, M.A., Huntley, B.K., and Maihle, N.J. 
1996. Ligand-independent dimerization of onco-
genic v-erbB products involves covalent interac-
tions. J. Virol. 70:2533–2544.
 28. Strong, J.E., Tang, D., and Lee, P.W.K. 1993. Evi-
dence that the epidermal growth factor receptor 
on host cells confers reovirus infection efficiency. 
Virology. 197:405–411.
 29. Wang, X., Huong, S.-M., Chiu, M.L., Raab-Traub, 
N., and Huang, E.-S. 2003. Epidermal growth 
factor receptor is a cellular receptor for human 
cytomegalovirus. Nature. 424:456–461.
 30. Yoo, J.-Y., and Desiderio, S. 2003. Innate and 
acquired immunity intersect in a global view of the 
acute-phase response. Proc. Natl. Acad. Sci. U. S. A. 
100:1157–1162.
 31. Selin, L.K., Varga, S.M., Wong, I.C., and Welsh, 
R.M. 1998. Protective heterologous antiviral 
immunity and enhanced immunopathogenesis 
mediated by memory T cell populations. J. Exp. 
Med. 188:1705–1715.
 32. Earl, P.L., Cooper, N., Wyatt, L.S., Moss, B., and 
Carroll, M.W. 2004. Preparation of cell cultures 
and vaccinia virus stocks. In Current Protocols in 
Molecular Biology. F.M. Ausubel et al., editors. John 
Wiley & Sons. New York, New York, USA. 16.16.
